Nestec S.a.

Societe Des Produits Nestle S.a.

Catherine Mace

Peter David Gluckman

Frederic Destaillats

Fabrizio Arigoni

Olivier Aprikian

Yassaman Shahkhalili Dulloo

Philip Newton Baker

Yap Seng Chong

Christian Darimont-Nicolau

Irma Silva Zolezzi

David Philippe

Keith Malcolm Godfrey

Cyrus Cooper

Etienne Pouteau

Lionel Bovetto

Lionel Jean Rene Bovetto

Markus Baur

Armand Malnoe

Marcelle Regnier

Carmen Tudorica

Marie-Claire Fichot

Elizabeth Offord Cavin

Peter Erdmann

Sagar Thakkar

Philippe Steenhout

Delphine Egli

Francesca Giuffrida

Magalie Sabatier

Andrea M A Pfeifer

Sandrine Gremlich

Christian Darimont

Kevin John Acheson

Florence Blancher

Kaori Minehira Castelli

Chieh Jason Chou

Geltrude Mingrone

Christian Darlmont

Joerg Hau

Yassaman Shahkhalili

Florence Budin

Lionel Jean René Bovetto

Olivier Kevork Aprikian

The present invention relates to whey protein micelles for use in the treatment and/or prevention of a disorder linked to an increase in plasma postprandial insulin and/or plasma postprandial glucagon concentration in a subject. The invention relates also to a non-therapeutic use of whey protein micelles to decrease plasma postprandial insulin and/or glucagon concentration in healthy subjects.

Use of whey protein micelles for improving insulin profile in diabetic patients

The present invention relates to a complementary nutritional composition characterized by a low glycemic load and/or index and/or comprising an ingredient characterized by a low glycemic index for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder appearing later in life.

Infant nutrition delivering metabolic benefits

Use of a lentil product to increase the bioavailability of non-haem iron in a composition comprising one or more anti-nutritional factors.

Nutritional composition

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of over-weight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to vitamin B12 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the off-spring, wherein the vitamin B12 is administered to an overweight and/or obese women desiring to get pregnant and/or to the over-weight and/or obese mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

Maternal vitamin B12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B6 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B6 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

Maternal vitamin B6 administration for the prevention of increased adiposity, overweight or obesity in the offspring

The present invention relates to a nutritional composition for use in treatment, prevention and/or reducing the risk of a metabolic syndrome disorder appearing later in life, wherein the nutritional composition comprises casein.

Infant nutrition for improvement in insulin sensitivity later in life

The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to vitamin B12 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B12 is administered to an overweight and/or obese women desiring to get pregnant and/or to the overweight and/or obese mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.

The invention relates to whey protein micelles for use in the treatment and/or prevention of a disorder linked to an increase in insulin secretion and/or plasma IGF-1 concentration in an infant at risk of developing obesity or diabetes. The invention also relates to a nutritional composition for infants comprising whey protein micelles. Further, the invention relates to a non-therapeutic use of a nutritional composition for infants, comprising whey protein micelles.

Use of whey protein micelles for infants at risk of obesity or diabetes

A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life.

Reduction of risk of obesity

A method of reducing the accumulation of fat mass in a neonatal human infant at risk thereof which method comprises administering to the infant during at least a part of the neonatal period a therapeutic amount of a nutritional composition comprising proteins in an amount such that the composition contains more than 2.4 g of protein per 100 kcal. As weight gain during the first week of life has been associated with overweight in adulthood, this may offer a method of reducing the risk of developing obesity in later life. Also claimed is the administration of DHA to the mother during gestation period.

Modulation of infant fat mass

The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to treat obesity. One embodiment of the present invention relates to the use ofCGMCC 1.3724 and/orNCC 4007 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.

[object Object]

Growing community of inventors

Lausanne, Switzerland

Catherine Mace